CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 163 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,405 | -26.2% | 2,631 | -9.0% | 0.04% | -24.1% |
| Q2 2023 | $98,126 | +8.5% | 2,892 | +15.1% | 0.06% | +16.0% |
| Q1 2023 | $90,418 | -41.7% | 2,513 | -27.8% | 0.05% | -38.3% |
| Q4 2022 | $155,104 | +14.0% | 3,480 | -28.2% | 0.08% | +50.0% |
| Q3 2022 | $136,000 | +4.6% | 4,847 | +0.6% | 0.05% | +12.5% |
| Q2 2022 | $130,000 | -7.8% | 4,816 | +16.6% | 0.05% | -23.8% |
| Q1 2022 | $141,000 | -16.6% | 4,131 | -5.7% | 0.06% | -1.6% |
| Q4 2021 | $169,000 | -60.2% | 4,382 | -44.3% | 0.06% | -65.8% |
| Q3 2021 | $425,000 | +52.9% | 7,865 | -5.2% | 0.19% | +64.0% |
| Q2 2021 | $278,000 | -18.0% | 8,300 | -49.6% | 0.11% | -20.3% |
| Q1 2021 | $339,000 | +19.8% | 16,464 | +1.8% | 0.14% | +22.2% |
| Q4 2020 | $283,000 | – | 16,174 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |